Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus murinus
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus murinus* is a commensal Gram-positive bacterial species typically found in the gastrointestinal tract of rodents and other mammals. In the context of therapeutic research, it is classified as a live biotherapeutic product (LBP) or probiotic. It is being investigated for its ability to modulate the host immune system and maintain intestinal barrier integrity. Research indicates that *L. murinus* can metabolize dietary components into bioactive molecules such as indole-3-acetaldehyde (IAAld). These metabolites act as ligands for the aryl hydrocarbon receptor (AhR) and influence macrophage polarization, shifting them toward an anti-inflammatory phenotype. This process subsequently inhibits pro-inflammatory signaling pathways, including NF-κB and TGF-β, thereby attenuating conditions like sepsis-induced acute intestinal injury and systemic inflammation.
- Other names
- L. murinus
02
Targets
AHR (Aryl hydrocarbon receptor)NF-κBTGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on lactobacillus murinus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus murinus.